

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10511537	
	Filing Date		2004-10-15	
	First Named Inventor	Tiden		
	Art Unit	1624		
	Examiner Name	Mark L. Berch		
Attorney Docket Number		100647-1P US		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5489598		1996-02-06	Connor et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20050070558		2005-03-31	Vidal Juan et al.	
	2	20070093483		2007-04-26	Svensson et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0359505	EP		1990-03-21	Smithkline Beecham Corporation		<input type="checkbox"/>
	2	0452926	EP		1996-03-13	Merrell Dow Pharmaceuticals Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10511537
Filing Date		2004-10-15
First Named Inventor	Tiden	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	100647-1P US	

3	02160235	JP		1990-06-20	Konica Corp		<input type="checkbox"/>
4	8906125	WO		1989-07-13	Smithkline Beechman Corporation		<input type="checkbox"/>
5	9914204	WO		1999-03-25	G.D. Searle & Co.		<input type="checkbox"/>
6	9940091	WO		1999-08-12	Amgen Inc.		<input type="checkbox"/>
7	0059449	WO		2000-10-12	Euro-Celtique S.A.		<input type="checkbox"/>
8	02006272	WO		2002-01-24	Sanofi-Synthelabo		<input type="checkbox"/>
9	02066447	WO		2002-08-29	Ono Pharmaceutical Co., Ltd		<input type="checkbox"/>
10	03000694	WO		2003-01-03	Almirall Prodesfarma S. A.		<input type="checkbox"/>
11	03082873	WO		2003-10-09	Almirall Prodesfarma S. A.		<input type="checkbox"/>
12	2004096781	WO		2004-11-11	AstraZeneca AB		<input type="checkbox"/>
13	2005042534	WO		2005-05-12	CV Therapeutics Inc.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Tiden
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

14	2006046910	WO		2006-05-04	AstraZeneca AB		<input type="checkbox"/>
15	2006062465	WO		2006-06-15	AstraZeneca AB		<input type="checkbox"/>
16	2007142576	WO		2007-12-13	AstraZeneca AB		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	IMAI et al., "Studies on Nucleic Acid Antagonists. VII. Synthesis and Characterization of 1,4,6-Triazaindenes (5H-Pyrrolo(3,2-d)pyrimidines)" Chem. Pharm. Bull., 1964, Vol. 12, No. 9, pgs. 1030-1042	<input type="checkbox"/>
	2	KOLASA et al., "Reactions of Alpha-Hydroxy Carbonyl Compounds With Azodicarboxylates and Triphenylphosphine: Synthesis of Alpha-N-Hydroxy Amino Acid Derivatives," Journal of Organic Chemistry, 1987, Vol. 52, pgs 4978-4984	<input type="checkbox"/>
	3	RAO et al., "Synthesis of 5,7-Disubstituted-4-Beta-D-ribofuranosylpyrazolo[4,3-d]-pyrimidines and 2,4-Disubstituted-1-Beta-D-ribofuranosylpyrrolo[3,2-d]-pyrimidines as Congeners of Uracil and Cytidine," J. Heterocyclic Chemistry, 1992, Vol. 29, pgs 343-354	<input type="checkbox"/>
	4	STN Intl, Registry No. 2487-40-3	<input type="checkbox"/>
	5	English abstract for JP 02160235	<input type="checkbox"/>
	6	English abstract for WO 2002006272	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Tiden
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

7	Co-Pending U.S. Application No. 11/756967, Attorney Docket No. 102288-2 US, filed on June 1, 2007	<input type="checkbox"/>
8	Co-Pending U.S. Application No. 11/577833, Attorney Docket No. 101584-1P US, filed on April 24, 2007	<input type="checkbox"/>
9	Co-Pending U.S. Application No. 11/720913, Attorney Docket No. 101621-1P US, filed on June 5, 2007	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.